I want to congratulate Fathy et al. [1], who investigated a mutant p53 and c-Myc oncoprotein expression levels in breast cancer (BC) patients with and without HCV infection. They reported that HCV infection may be accompanied by BC severity, owing to the elevated expression of mutant p53 and c-Myc oncoproteins. However, the authors did not describe distribution of breast cancer subtypes in BC patients with and without HCV infection. Myc is elevated in triple-negative BC compared with other cancer subtypes. Interestingly, Myc-driven pathways are further elevated in aggressive breast cancer cells and tumors that display drug-resistant phenotype [2]. One study showed that the mutation spectrum of TP53 varied between the BC subtypes, and individual alterations showed subtype-specific association. TP53 mutations were associated with increased mortality in patients with luminal B, HER2-enriched, and normal-like tumors, but not in patients with luminal A and basal-like tumors [3]. Taken all together, it makes sense that BC subtypes in BC patients with and without hepatitis C virus infection might differ. This is a matter that needs more research.